-
1 day ago | 
optometrytimes.com | AnnMarie Hipsley |Emily Kaiser Maharjan |Sheryl Stevenson |Hattie Hayes
At the 2025 ASCRS meeting in Los Angeles, a concept was shared by AnnMarie Hipsley, DPT, PhD, for optometrists seeking to stay at the forefront of precision ocular care—the Digital Twin. More than a buzzword, a digital twin represents a virtual simulation of a real-world anatomical system, in this case, the human eye.
-
5 days ago | 
optometrytimes.com | Mark Bullimore |Martin Harp |Hattie Hayes |Emily Kaiser Maharjan
At the 2025 ARVO conference in Salt Lake City, Mark Bullimore, MCOptom, PhD, of the University of Houston College of Optometry shared a compelling critique of the current use of centile growth curves for axial length in myopia management. Speaking directly to optometrists, Bullimore emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy. Centile growth curves based on general populations are misleading in myopia management.
-
6 days ago | 
optometrytimes.com | Emily Kaiser Maharjan
Cognition Therapeutics reported topline results for the phase 2 Magnify trial of the oral medication zervimesine intended to slow lesion growth in patients with geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD). At 18 months, patients who were treated with zervimesine had 28.6% slower GA lesion growth and their lesions were 28.2% smaller than patients in the placebo growth.
-
6 days ago | 
optometrytimes.com | Emily Kaiser Maharjan
Boehringer Ingelheim announced the start of the JADE and VERDANT phase 2 clinical studies to investigate the safety and efficacy of 2 candidates: BI 1584862, a potential first-in-class oral compound for the treatment of geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD)1; and BI 771716, an antibody fragment, respectively. BI 1584862 is a phospholipid modulator intended to preserve patient vision by targeting inflammation and preserving vascular function.
-
6 days ago | 
optometrytimes.com | Emily Kaiser Maharjan
Today, Luminopia announced that its amblyopia treatment has been approved by Anthem Blue Cross and Blue Shield for insurance coverage.1 The news comes on the heels of the FDA’s age extension of clearance for Luminopia’s amblyopia treatment, now indicating treatment from patients aged 4 to 7 to patients aged 4 to 12 years.2 Both are steps toward expanding access to the unique, entertainment-based amblyopia treatment nationwide.
-
1 week ago | 
optometrytimes.com | Emily Kaiser Maharjan
Aldeyra Therapeutics has achieved primary end point in one of their phase 3 trials of reproxalap for the treatment of dry eye disease, which the company will include in the resubmission of the new drug application (NDA) for the therapeutic candidate.1 The dry eye chamber trial was statistically superior to the vehicle in terms of ocular discomfort and while the field trial missed statistical significance for the primary end point, it was consistent with previous field trials and will be...
-
1 week ago | 
optometrytimes.com | Paul Hammond |Hattie Hayes |Martin Harp |Emily Kaiser Maharjan
At ARVO 2025, Paul Hammond, OD, FAAO, of Twin Cities Eye Consultants shared pivotal findings in a poster aimed at solving a common clinical challenge: how to preserve the integrity of glaucoma progression data when switching OCT platforms. ARVO took place in Salt Lake City from May 4-8, 2025. Bridging the gap Between OCT DevicesConversion factors matter: Having a reliable method to translate GCIPL and RNFL data between OCT platforms can preserve continuity in glaucoma care.
-
1 week ago | 
optometrytimes.com | Dilsher S. Dhoot |Emily Kaiser Maharjan |Hattie Hayes
At the 2025 Controversies in Modern Eye Care conference, Dilsher Dhoot, MD, FASRS, of California Retina Consultants shared his forward-looking perspective on developments in retinal disease management, highlighting both recent breakthroughs and promising innovations on the horizon. The Controversies in Modern Eye Care meeting took place on May 4, 2025, in Los Angeles, California. GA management is evolving: New therapies exist, and more are coming with enhanced durability and efficacy.
-
1 week ago | 
ophthalmologytimes.com | Robert Maloney |Hattie Hayes |Emily Kaiser Maharjan
At this year’s Controversies in Modern Eye Care (CIME) meeting in Los Angeles, one of the most compelling sessions, given by Robert Maloney, MD, MA, wasn’t about the newest device or drug—it was about history. Specifically, the moment 75 years ago when Harold Ridley implanted the first intraocular lens (IOL) in a human eye. This landmark event reshaped ophthalmology forever.
-
1 week ago | 
optometrytimes.com | Jacob Lang |Hattie Hayes |Emily Kaiser Maharjan
At the Controversies in Modern Eye Care meeting in Los Angeles, California, which took place on May 4, 2025, Jacob Lang, OD, FAAO, director of dry eye services at Associated Eye Care in the Twin Cities metro area, shared his perspective on one of the most exciting advancements in vision care: pharmacologic correction for presbyopia. A new frontier in presbyopia managementPharmacologic presbyopia treatments offer patients increased flexibility and lifestyle freedom.
